Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials

EJ Gane; S Pianko; SK Roberts; AJ Thompson; S Zeuzem; E Zuckerman; Z Ben-Ari; GR Foster; K Agarwal; AL Laursen; J Gerstoft; W Gao; HC Huang; B Fitzgerald; D Fernsler; JJ Li; A Grandhi; H Liu; FH Su; S Wan; Z Zeng; HL Chen; FJ Dutko; BYT Nguyen; J Wahl; MN Robertson; E Barr; WW Yeh; RM Plank; JR Butterton; R Esteban

Journal article

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials

EJ Gane, S Pianko, SK Roberts, AJ Thompson, S Zeuzem, E Zuckerman, Z Ben-Ari, GR Foster, K Agarwal, AL Laursen, J Gerstoft, W Gao, HC Huang, B Fitzgerald, D Fernsler, JJ Li, A Grandhi, H Liu, FH Su, S Wan Show all

Lancet Gastroenterology and Hepatology | ELSEVIER INC | Published : 2017

DOI: 10.1016/S2468-1253(17)30159-0

Abstract

Background New hepatitis C virus (HCV) therapies with pan-genotypic efficacy are needed. The goals of part A of C-CREST-1 and C-CREST-2 were to compare the efficacies of two doses (300 mg or 450 mg once daily) of uprifosbuvir (MK-3682; NS5B inhibitor) in an 8-week regimen combined with grazoprevir (NS3/4A inhibitor; 100 mg once daily) and an NS5A inhibitor, either elbasvir (50 mg once daily) or ruzasvir (MK-8408; 60 mg once daily), and to evaluate the safety and tolerability of these combination regimens in individuals infected with genotypes 1, 2, or 3. Methods Part A of these phase 2, randomised, multicentre, open-label, clinical trials enrolled participants from 11 countries, aged 18 year..

View full abstract